In these experiments the MEK inhibition-dependent upregulation of MHC on tumours was further enhanced by immunotherapy dependent expression of IFN-γ, providing a mechanism by which combined therapy synergised to enhance T-cell responses. Here, MAP2K7 is linked to neoplasm.